Notre groupe organise plus de 3 000 séries de conférences Événements chaque année aux États-Unis, en Europe et en Europe. Asie avec le soutien de 1 000 autres Sociétés scientifiques et publie plus de 700 Open Access Revues qui contiennent plus de 50 000 personnalités éminentes, des scientifiques réputés en tant que membres du comité de rédaction.
Les revues en libre accès gagnent plus de lecteurs et de citations
700 revues et 15 000 000 de lecteurs Chaque revue attire plus de 25 000 lecteurs
Kalyani D
Cancer continues to be a global health challenge, affecting millions of people worldwide and posing significant morbidity and mortality rates. In this study, we aimed to investigate and analyze the oncological outcomes in cancer patients to gain a comprehensive understanding of prognosis and treatment effectiveness. We conducted a retrospective analysis of a large cohort of cancer patients from multiple medical centers, spanning diverse cancer types and stages. Data from electronic health records, medical imaging, pathology reports, and treatment regimens were collected for each patient. The analysis focused on several key aspects of oncological outcomes, including overall survival rates, disease-free survival, progression-free survival, and response rates to various therapeutic modalities. Additionally, we explored the impact of various prognostic factors, such as cancer type, stage at diagnosis, genetic mutations, and patient demographics. Our findings revealed significant variations in oncological outcomes across different cancer types and stages. We identified specific cancer types that showed promising treatment responses and those with poorer prognosis, enabling us to pinpoint areas requiring further research and therapeutic advancements. Moreover, we observed the influence of patient-specific factors on treatment outcomes, emphasizing the importance of personalized medicine in oncology. Furthermore, we analyzed the impact of different treatment approaches, including surgery, chemotherapy, radiation therapy, targeted therapies, and immunotherapies, on patient survival and quality of life. This analysis shed light on the effectiveness of specific treatments and highlighted potential areas for treatment optimization and enhancement. To better understand long-term outcomes, we also examined the role of survivorship care in cancer management, focusing on post-treatment complications, recurrence monitoring, and survivorshiprelated challenges.